Clinical trial
Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell…
NCT00057889 · National Institutes of Health Clinical Center (CC), NIH · Completed
Key facts
| NCT number | NCT00057889 |
|---|---|
| Title | Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer |
| Official title | A Phase II Open-Label Study of Single Agent MDX-010 for the Treatment of IL-2 Refractory or IL-2 Ineligible Patients With Stage IV Renal Cancer |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Biological |
| Interventions | ipilimumab |
| Start date | Feb 1, 2003 |
| Primary completion | Oct 1, 2007 |
| Completion | Feb 1, 2008 |
| First posted | Apr 9, 2003 |
| Last update posted | Mar 15, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: